Log in

Start Your Membership Now

Mindset Pharma Inc. (Mindset), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, announced that, under its Co-operative Psychedelics Evaluation Platform (COPE) program with InterVivo Solutions (InterVivo), the Company has further developed its first generation psychedelics benchmarking data by establishing standard pharmacokinetic, brain penetration, and drug discrimination data and protocols across lysergic acid diethylamide (LSD), psilocybin, and o-methyl-bufotenin (5-MeO-DMT).

The COPE Program is a translational testing platform developed in cooperation with InterVivo to introduce an industry standard against . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
Log In
If you are already a member, log in to your account to access this resource and more.

Become A Free Member
You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

Tagged As: